Xencor, Inc. (XNCR) Dividend History

Company News

• Xencor (XNCR) Q2 Revenue Jumps 82%

  Xencor reported strong Q2 2025 financial performance with revenue of $43.6 million, beating estimates by 93%. The company advanced several clinical programs in oncology and autoimmune disorders and received a significant milestone payment from Incyte.

  The Motley Fool
• [Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

  The global Ultomiris drug market is expected to grow from USD 4.16 Billion in 2024 to USD 64.12 Billion by 2034, with a robust 31.52% CAGR, driven by increasing demand for long-acting treatments for rare disorders like PNH and gMG.

  GlobeNewswire Inc.
• Xencor Surges 10.5%: Is This an Indication of Further Gains?

  Xencor shares surged 10.5% after the company announced a secondary stock offering to raise $175 million. The company plans to use the funds to support its pipeline development. However, earnings and revenue expectations for the upcoming quarter are negative, which may impact the stock's future performance.

  Benzinga

  Featured Companies: USNA
• Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

  Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  Zacks Investment Research

  Featured Companies: FENC
• The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks

  A more selective small-cap index has consistently outperformed the Russell 2000

  MarketWatch

  Featured Companies: ACRV ALLO ARLO ATNM CMPX CPRX CRBU DGII DVAX GPRE HLX IJR INZY IPSC IRWD IWM KPTI LCTX LGND MODV PAYO PCRX PRVA PTEN RCUS RLYB RNA SMTC SPY STOK TALO THRY TNYA TRVI VIGL VIR VOR XFOR XPER